|
|
News Breaks
|
February 10, 2012
|
| 15:30 EDT |  | WPI, BAYRY |
| theflyonthewall.com: | Watson sued by Bayer over birth control patent, Bloomberg reports | | Watson Pharmaceuticals (WPI) is being sued by a unit of Bayer (BAYRY) for violating a patent in trying to develop a generic of Bayer' Beyaz birth control pills, reported Bloomberg, citing court filings. Reference Link :theflyonthewall.com |
|
|
News For WPI;BAYRY From The Last 14 Days Check below for free stories on WPI;BAYRY the last two weeks.
There are 10 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 24, 2012
|
| 16:09 EDT |  | WPI |
| theflyonthewall.com: | Watson confirms Testim patent challenge, Paragraph IV litigation underway | | Watson Pharmaceuticals (WPI) confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals' (AUXL) Testim® 1%. Testim®1% is indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. Auxilium and FCB I LLC filed suit against Watson on May 23 in the United States District Court for the District of New Jersey seeking to prevent Watson from commercializing its 1% testosterone gel product prior to the expiration of certain U.S. patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. :theflyonthewall.com |
| | 10:29 EDT |  | WPI |
| | 07:13 EDT |  | BAYRY |
| theflyonthewall.com: | J&J's Xarelto likely delayed 3-12 months, not dead, says Leerink | | Leerink believes the FDA panel vote against approval of Johnson & Johnson's (JNJ) and Bayer's (BAYRY) Xarelto for the prevention of CV events in patients with a recent acute coronary syndrome will likely delay approval by 3-12 months, not kill the drug for this indication. The firm believes Bristol-Myers' (BMY) and Pfizer's (PFE) Eliquis could benefit slightly from a Xarelto delay. :theflyonthewall.com |
| | 05:59 EDT | | WPI |
|
|
May 23, 2012
|
| 16:21 EDT | | BAYRY |
| | 12:03 EDT | | BAYRY |
| theflyonthewall.com: | Bayer submits NDA for Regorafenib for treatment of metastatic colorectal cancer |
 Subscribe for More Information :theflyonthewall.com |
|
|
May 22, 2012
|
| 06:04 EDT | | BAYRY |
| theflyonthewall.com: | Onyx, Bayer say Phase 3 Nexavar trial did not meet endpoint | | Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) announced that a Phase 3 trial evaluating Nexavar tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival. An improvement in the secondary endpoint of progression-free survival was observed. The study compared Nexavar plus best supportive care to placebo plus best supportive care. The safety and tolerability data were generally as expected. The data will be presented at an upcoming scientific meeting. "While we are disappointed that the primary endpoint was not met, we believe the study results will advance the scientific knowledge in lung cancer," said Dr. Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. :theflyonthewall.com |
|
|
May 21, 2012
|
| 07:38 EDT |  | BAYRY |
|
|
May 17, 2012
|
| 08:57 EDT | | WPI |
|
|
May 14, 2012
|
| 09:03 EDT | | BAYRY |
|
|
|
|
|
